Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma

Saerom Choi, Jung Woo Han, Hyosun Kim, Beom Sik Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and retrospectively reviewed the efficacy and safety of this approach. Methods: Patients diagnosed with intraocular RB between January 2000 and December 2011 at Severance Children's Hospital, Yonsei University, were reviewed. Before February 2010, the primary treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy (HDCTX) were used as "last resort" treatments just prior to enucleation at the time of progression or recurrence during primary treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. Results: We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 eyes, of which, 60.0% were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3% at early RE stages and 81.8% at advanced RE stages (P =0.028). At 36 months, EFS was significantly higher in the IAC/CTX group than in the non-IAC/CTX group (100.0% vs. 40.0%, P=0.016). All 5 patients treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV-V). Conclusion: Despite the limitation of a small sample size, our work shows that an alternative combined approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.

Original languageEnglish
Pages (from-to)254-259
Number of pages6
JournalKorean Journal of Pediatrics
Volume56
Issue number6
DOIs
Publication statusPublished - 2013 Jun

Fingerprint

Retinoblastoma
Drug Therapy
Therapeutics
Sample Size
Disease-Free Survival
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Pediatrics

Cite this

Choi, Saerom ; Han, Jung Woo ; Kim, Hyosun ; Kim, Beom Sik ; Kim, Dong Joon ; Lee, Sung Chul ; Lyu, Chuhl Joo. / Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma. In: Korean Journal of Pediatrics. 2013 ; Vol. 56, No. 6. pp. 254-259.
@article{7ba69d4004034c349df17bae694f2158,
title = "Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma",
abstract = "Purpose: Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and retrospectively reviewed the efficacy and safety of this approach. Methods: Patients diagnosed with intraocular RB between January 2000 and December 2011 at Severance Children's Hospital, Yonsei University, were reviewed. Before February 2010, the primary treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy (HDCTX) were used as {"}last resort{"} treatments just prior to enucleation at the time of progression or recurrence during primary treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. Results: We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 eyes, of which, 60.0{\%} were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3{\%} at early RE stages and 81.8{\%} at advanced RE stages (P =0.028). At 36 months, EFS was significantly higher in the IAC/CTX group than in the non-IAC/CTX group (100.0{\%} vs. 40.0{\%}, P=0.016). All 5 patients treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV-V). Conclusion: Despite the limitation of a small sample size, our work shows that an alternative combined approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.",
author = "Saerom Choi and Han, {Jung Woo} and Hyosun Kim and Kim, {Beom Sik} and Kim, {Dong Joon} and Lee, {Sung Chul} and Lyu, {Chuhl Joo}",
year = "2013",
month = "6",
doi = "10.3345/kjp.2013.56.6.254",
language = "English",
volume = "56",
pages = "254--259",
journal = "Korean Journal of Pediatrics",
issn = "1783-1061",
publisher = "Korean Pediatric Society",
number = "6",

}

Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma. / Choi, Saerom; Han, Jung Woo; Kim, Hyosun; Kim, Beom Sik; Kim, Dong Joon; Lee, Sung Chul; Lyu, Chuhl Joo.

In: Korean Journal of Pediatrics, Vol. 56, No. 6, 06.2013, p. 254-259.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma

AU - Choi, Saerom

AU - Han, Jung Woo

AU - Kim, Hyosun

AU - Kim, Beom Sik

AU - Kim, Dong Joon

AU - Lee, Sung Chul

AU - Lyu, Chuhl Joo

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and retrospectively reviewed the efficacy and safety of this approach. Methods: Patients diagnosed with intraocular RB between January 2000 and December 2011 at Severance Children's Hospital, Yonsei University, were reviewed. Before February 2010, the primary treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy (HDCTX) were used as "last resort" treatments just prior to enucleation at the time of progression or recurrence during primary treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. Results: We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 eyes, of which, 60.0% were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3% at early RE stages and 81.8% at advanced RE stages (P =0.028). At 36 months, EFS was significantly higher in the IAC/CTX group than in the non-IAC/CTX group (100.0% vs. 40.0%, P=0.016). All 5 patients treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV-V). Conclusion: Despite the limitation of a small sample size, our work shows that an alternative combined approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.

AB - Purpose: Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and retrospectively reviewed the efficacy and safety of this approach. Methods: Patients diagnosed with intraocular RB between January 2000 and December 2011 at Severance Children's Hospital, Yonsei University, were reviewed. Before February 2010, the primary treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy (HDCTX) were used as "last resort" treatments just prior to enucleation at the time of progression or recurrence during primary treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. Results: We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 eyes, of which, 60.0% were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3% at early RE stages and 81.8% at advanced RE stages (P =0.028). At 36 months, EFS was significantly higher in the IAC/CTX group than in the non-IAC/CTX group (100.0% vs. 40.0%, P=0.016). All 5 patients treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV-V). Conclusion: Despite the limitation of a small sample size, our work shows that an alternative combined approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.

UR - http://www.scopus.com/inward/record.url?scp=84879165836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879165836&partnerID=8YFLogxK

U2 - 10.3345/kjp.2013.56.6.254

DO - 10.3345/kjp.2013.56.6.254

M3 - Article

C2 - 23807892

AN - SCOPUS:84879165836

VL - 56

SP - 254

EP - 259

JO - Korean Journal of Pediatrics

JF - Korean Journal of Pediatrics

SN - 1783-1061

IS - 6

ER -